PPARG and non-small cell lung carcinoma: In this connection, a preliminary clinical study of pioglitazone as potential neoadjuvant therapy in non-small-cell lung cancer is currently underway, while two phase I studies of a novel PPAR-γ agonist in combination with the established chemotherapeutic agents carboplatin/paclitaxel or erlotinib in patients with non-small-cell lung cancer have recently been completed.